| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1030947514 |
| P356 | DOI | 10.2165/00003088-199834060-00003 |
| P698 | PubMed publication ID | 9646008 |
| P2093 | author name string | K Nelson | |
| B Heintz | |||
| D Kirsten | |||
| R Kirsten | |||
| P2860 | cites work | Metabolism of hydralazine by activated leukocytes: implications for hydralazine induced lupus | Q28237363 |
| Felodipine Clinical Pharmacokinetics | Q28325479 | ||
| Lithium and calcium channel blockers: possible neurotoxicity | Q28333730 | ||
| Enalapril: a well-tolerated and efficacious agent for the pediatric hypertensive patient | Q28340505 | ||
| Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group | Q28342399 | ||
| Regulation of contraction and relaxation in arterial smooth muscle | Q30439132 | ||
| A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril | Q33189033 | ||
| Drug dosing guidelines in patients with renal failure | Q33560300 | ||
| Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators | Q33613576 | ||
| Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide | Q34117938 | ||
| Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases | Q34172660 | ||
| The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril | Q34345707 | ||
| The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure | Q34346175 | ||
| Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil | Q34347537 | ||
| Pharmacokinetic drug interactions with ACE inhibitors | Q34353037 | ||
| The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment | Q34357537 | ||
| A comparison of the pharmacokinetics of nisoldipine in elderly and young subjects | Q34358077 | ||
| A population study of the pharmacokinetics of felodipine | Q34358245 | ||
| Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension | Q34396973 | ||
| Pharmacokinetics of cilazapril in patients with renal failure | Q34397134 | ||
| The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure | Q34397224 | ||
| Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration | Q34417089 | ||
| The effect of ageing on the disposition of nifedipine and atenolol | Q34417199 | ||
| Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis | Q34418226 | ||
| Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat | Q34447399 | ||
| The effects of oral nitrendipine and propranolol, alone and in combination, on hypertensive patients with special reference to AV conduction | Q34448055 | ||
| Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | Q34539986 | ||
| Clinical pharmacokinetics of amlodipine | Q34550434 | ||
| Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue. | Q34570099 | ||
| Pharmacokinetics and Response to Diazoxide in Renal Failure | Q34686999 | ||
| Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist | Q71378091 | ||
| Nifedipine: kinetics and dynamics in healthy subjects | Q71388551 | ||
| Clinical relevance of verapamil plasma levels in stable angina pectoris | Q71450736 | ||
| High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil | Q71499835 | ||
| Nifedipine reduces thromboxane A2 production by platelets without changing aggregation in hypertensive pregnancy | Q71584936 | ||
| Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations | Q71633115 | ||
| The effect of acute volume expansion and vasodilatation with verapamil on uterine and umbilical artery Doppler indices in severe preeclampsia | Q71636763 | ||
| Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin | Q71650801 | ||
| Pharmacokinetic and pharmacodynamic effects of diltiazem | Q71721985 | ||
| Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes | Q71751276 | ||
| Pharmacokinetics of diltiazem in severe renal failure | Q71792159 | ||
| Human Plasma Protein Binding of the Angiotensin II Receptor Antagonist Losartan Potassium (DuP 753/MK 954) and Its Pharmacologically Active Metabolite EXP3174 | Q72017520 | ||
| Preventive effects of diltiazem on cyclosporin A-induced vascular smooth muscle dysfunction | Q72129196 | ||
| Disposition of captopril in normal subjects | Q72132482 | ||
| Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators | Q72232746 | ||
| A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension | Q72282359 | ||
| [Calcium antagonists in pregnancy as an antihypertensive and tocolytic agent] | Q72308519 | ||
| [Overdosing on diltiazem in heptic insufficiency] | Q72347931 | ||
| Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers | Q72383330 | ||
| Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency | Q72383337 | ||
| Captopril treatment of chronic heart failure in the very old | Q72388864 | ||
| Novel cardiac myofilament desensitizing factor released by endocardial and vascular endothelial cells | Q72523252 | ||
| Effect and tolerability of combining lovastatin with nifedipine or lisinopril | Q72548826 | ||
| Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure | Q72564512 | ||
| Efficacy of minoxidil in the treatment of severe hypertension in systemic disorders | Q72612365 | ||
| Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients | Q72745782 | ||
| Occurrence of autoantibodies directed against myeloperoxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis | Q72770171 | ||
| Infarct-related heart failure: the choice of ACE inhibitor does not matter | Q72772535 | ||
| [Intrauterine therapy of fetal supraventricular tachycardia with digoxin and verapamil] | Q72823713 | ||
| Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure | Q72968973 | ||
| Use of nifedipine in hypertrophic cardiomyopathy in infants. A report of two cases | Q93606283 | ||
| Angiotensin II receptors and angiotensin II receptor antagonists. | Q40846126 | ||
| Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure | Q40891443 | ||
| Similarities and differences between calcium antagonists: pharmacological aspects. | Q40902112 | ||
| Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review | Q40959796 | ||
| Treatment of Severe Hypertension with Minoxidil: Advantages and Limitations | Q41035180 | ||
| Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension. Response to captopril | Q41180523 | ||
| The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers | Q41307636 | ||
| Bioequivalence of controlled-release calcium antagonists | Q41333152 | ||
| Nitrendipine kinetics in normal and impaired renal function | Q41394354 | ||
| Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses | Q41816741 | ||
| The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily | Q41855699 | ||
| Hydralazine induces Z-DNA conformation in a polynucleotide and elicits anti(Z-DNA) antibodies in treated patients | Q41875776 | ||
| Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects | Q42064858 | ||
| Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans | Q42084127 | ||
| Nifedipine in hypertensive crises of infants and children | Q42085862 | ||
| Nifedipine in hypertensive emergencies of children. | Q42089457 | ||
| Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction | Q42201560 | ||
| The pharmacokinetics of enalapril in patients with compensated liver cirrhosis | Q42229384 | ||
| Enalapril maleate and a lysine analogue (MK-521): disposition in man | Q42264743 | ||
| Pharmacokinetics of felodipine in patients with impaired renal function | Q42277034 | ||
| Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension | Q42278661 | ||
| Chronic hepatitis caused by lisinopril | Q42281244 | ||
| Comparison of nifedipine alone and with diltiazem or verapamil in hypertension | Q42632868 | ||
| Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. | Q42685488 | ||
| Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine | Q43229081 | ||
| Steady-state kinetics of ramipril in renal failure | Q43526648 | ||
| Treatment of hypertensive crisis in children with nifedipine | Q43630743 | ||
| Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter | Q43903103 | ||
| Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure | Q43924677 | ||
| Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function | Q43974655 | ||
| Single- and multiple-dose nisoldipine kinetics and effects in the young, the middle-aged, and the elderly. | Q44224379 | ||
| Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing | Q44264216 | ||
| The pharmacokinetics of captopril in infants with congestive heart failure | Q44309698 | ||
| Blood pressure effects of the angiotensin II receptor blocker, losartan | Q44651090 | ||
| Increased cyclosporine blood concentrations due to verapamil administration. | Q44681130 | ||
| The pharmacokinetics of losartan in renal insufficiency | Q44941439 | ||
| Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients on chronic hemodialysis | Q45033195 | ||
| Aging alters verapamil elimination and dynamics: single dose and steady-state responses. | Q45902875 | ||
| Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. | Q46058929 | ||
| The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil | Q46103117 | ||
| Interaction between Ca2+ antagonists and digitalis | Q46168562 | ||
| Nitrendipine in the treatment of mild to moderate hypertension | Q46191872 | ||
| Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype. | Q46346335 | ||
| The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. | Q46725646 | ||
| Pharmacokinetics of nitrendipine in terminal renal failure | Q46729707 | ||
| Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure | Q46969882 | ||
| Pharmacokinetics of verapamil in patients with renal failure | Q49323041 | ||
| The influence of age on the pharmacokinetics of nimodipine. | Q51006137 | ||
| Age and severe adverse drug reactions caused by nifedipine and verapamil. Gruppo Italiano di Farmacovigilanza nell' Anziano (GIFA). | Q51024226 | ||
| The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. | Q51622309 | ||
| Relative bioavailability of immediate- and sustained-release hydralazine formulations. | Q51623628 | ||
| Pharmacokinetics of nilvadipine in healthy volunteers. | Q51630558 | ||
| Influence of Food on the Bioavailability of Enalapril | Q51640991 | ||
| Effects of short-term infusion of nifedipine or verapamil on systemic hemodynamics and left ventricular myocardial contractility in patients prior to coronary artery bypass surgery. | Q51783912 | ||
| Verapamil kinetics in normal subjects and patients with coronary artery spasm | Q52733119 | ||
| Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition | Q52873684 | ||
| [Therapy with ACE inhibitors in chronic heart failure and limited kidney function]. | Q53019759 | ||
| The physiological disposition and metabolism of enalapril maleate in laboratory animals | Q34707277 | ||
| Impairment of captopril bioavailability by concomitant food and antacid intake | Q34709053 | ||
| Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects | Q34713722 | ||
| Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension | Q35316601 | ||
| Absence of interaction between ramipril, a new ACE-inhibitor, and phenprocoumon, an anticoagulant agent | Q35334829 | ||
| Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders | Q35336765 | ||
| Management of hypertensive emergencies | Q35627887 | ||
| Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group | Q35717158 | ||
| Comparative pharmacokinetics of captopril, enalapril, and quinapril | Q35909974 | ||
| Clinical pharmacokinetics of calcium antagonists. An update | Q36115910 | ||
| Transfected cGMP-dependent protein kinase suppresses calcium transients by inhibition of inositol 1,4,5-trisphosphate production | Q36188558 | ||
| Reactive hypoglycemic coma due to insulin autoimmune syndrome: Case report and literature review | Q36211324 | ||
| Quinapril. A review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders | Q36657490 | ||
| Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. | Q36681011 | ||
| Management of hypertensive emergencies: Changing therapeutic options | Q36886754 | ||
| Minoxidil in resistant hypertension | Q36896502 | ||
| Surgical bleeding: unexpected effect of a calcium antagonist | Q36902881 | ||
| Pharmacokinetic Interactions with Calcium Channel Antagonists (Part I)1 | Q36923321 | ||
| Cardiac hypertrophy. Mechanical, neural, and endocrine dependence | Q37075902 | ||
| Clinical pharmacology, pharmacokinetics, and hemodynamic effects of nicardipine | Q37579267 | ||
| Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders | Q37850376 | ||
| Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease | Q37858050 | ||
| New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization | Q37876905 | ||
| Drug interactions with calcium antagonists | Q38140205 | ||
| The clinical pharmacology of lisinopril | Q38178569 | ||
| Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease | Q38201054 | ||
| Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents | Q38216387 | ||
| Calcium channel blockers as inhibitors of drug metabolism | Q38358372 | ||
| Overall tolerance and safety of quinapril in clinical trials | Q38617225 | ||
| Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure | Q38631261 | ||
| Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease | Q38658267 | ||
| Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension | Q38679740 | ||
| Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure | Q39264075 | ||
| Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow | Q39284510 | ||
| Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics | Q39299391 | ||
| Drug interactions with the calcium-entry blockers | Q39462324 | ||
| Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure | Q39501948 | ||
| Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure | Q39554955 | ||
| Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension | Q39567108 | ||
| Clinical pharmacology of verapamil | Q39610558 | ||
| Interactions between calcium channel blockers and non-cardiovascular drugs: interactions with drugs acting at the neuromuscular or the CNS level | Q39634726 | ||
| Clinical pharmacokinetics of felodipine. A summary | Q39697154 | ||
| Clinical pharmacokinetics of verapamil, nifedipine and diltiazem | Q39754378 | ||
| Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension | Q39764429 | ||
| Clinical digoxin toxicity in the aged in association with co-administered verapamil. A report of two cases and review of the literature | Q39792360 | ||
| Diltiazem. A review of its pharmacological properties and therapeutic efficacy | Q39822461 | ||
| Verapamil/beta-blocker interaction. A review. | Q40092334 | ||
| Pharmacology and Pharmacokinetics of Minoxidil | Q40098145 | ||
| Minoxidil: a review of its pharmacological properties and therapeutic use. | Q40319953 | ||
| Gallopamil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in ischaemic heart disease | Q40387205 | ||
| Individualised selection of antihypertensive therapy. | Q40387888 | ||
| Vascular Versus Myocardial Effects of Calcium Antagonists | Q40393261 | ||
| Intracellular mechanisms involved in the regulation of vascular smooth muscle tone | Q40430183 | ||
| Modulation of the renin-angiotensin-aldosterone system and cough | Q40476436 | ||
| Stereoselective pharmacokinetics of dihydropyridine calcium antagonists | Q40507979 | ||
| Treatment of hypertension in nondiabetic renal disease. | Q40629696 | ||
| Hydralazine boluses for the treatment of severe hypertension in pre-eclampsia | Q40665234 | ||
| Clinical pharmacokinetics of ramipril | Q40730358 | ||
| Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. | Q40756584 | ||
| Mechanical and other factors relating to left ventricular hypertrophy. | Q40763417 | ||
| Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase | Q40764514 | ||
| Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview | Q40791108 | ||
| Individual variation in first-pass metabolism | Q40791116 | ||
| Hepatotoxicity associated with angiotensin-converting enzyme inhibitors. | Q40806582 | ||
| Usefulness of amlodipine for angina pectoris | Q40815726 | ||
| Worsening of anemia induced by long-term use of captopril in hemodialysis patients | Q40831010 | ||
| Pharmacokinetics, pharmacodynamics, and minimum effective clinical dose of intravenous nicardipine | Q68825090 | ||
| Felodipine-induced dilatation of epicardial coronary arteries. A randomized, double-blind study | Q68860167 | ||
| Pharmacokinetics of captopril in elderly healthy male volunteers | Q68872982 | ||
| Plasma protein binding and erythrocyte partitioning of nicardipine in vitro | Q68943517 | ||
| Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog | Q68974693 | ||
| Effects of single and repeated doses of the calcium antagonist felodipine on blood pressure, renal function, electrolytes and water balance, and renin-angiotensin-aldosterone system in hypertensive patients | Q68986268 | ||
| Tolerance and cardiovascular effects of single dose felodipine/beta-blocker combinations in healthy subjects | Q69003289 | ||
| The influence of antituberculosis drugs on the plasma level of verapamil | Q69021328 | ||
| Verapamil pharmacodynamics and disposition in obese hypertensive patients | Q69025113 | ||
| A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects | Q69058199 | ||
| Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects | Q69067564 | ||
| Circadian variation in the pharmacokinetics of verapamil | Q69426482 | ||
| Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients | Q69443400 | ||
| [Pharmacokinetics and metabolism of gallopamil] | Q69458303 | ||
| Variability in the pharmacokinetics of nisoldipine as caused by differences in liver blood flow response | Q69723992 | ||
| Electrophysiological mechanisms of minoxidil sulfate-induced vasodilation of rabbit portal vein | Q69747775 | ||
| Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure | Q69749403 | ||
| Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function | Q69824404 | ||
| Pharmacokinetics of lisinopril | Q69837908 | ||
| Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure | Q69912198 | ||
| Increased quinidine plasma concentrations during administration of verapamil: a new quinidine-verapamil interaction | Q70024216 | ||
| Absorption, distribution and elimination of felodipine in man | Q70087050 | ||
| The effect of renal function on enalapril kinetics | Q70109312 | ||
| Antihypertensive effect and pharmacokinetics of nitrendipine in children | Q70124456 | ||
| Captopril in human blood and breast milk | Q70148470 | ||
| Pharmacokinetics of oral diltiazem and five of its metabolites in patients with chronic renal failure | Q70153782 | ||
| Clinical pharmacology of ramipril | Q70177638 | ||
| Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients | Q70177642 | ||
| Pharmacokinetics of ramipril in the elderly | Q70177645 | ||
| The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses | Q70283797 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group | Q70733060 | ||
| Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension | Q70758756 | ||
| Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans | Q70806295 | ||
| Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension | Q70873253 | ||
| Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin | Q70915972 | ||
| Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients | Q70944526 | ||
| L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study | Q71047041 | ||
| Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function | Q71132667 | ||
| Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine | Q71340071 | ||
| Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age | Q71342697 | ||
| The pharmacokinetics of extended release felodipine in children | Q71344953 | ||
| Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists. | Q53895442 | ||
| Pharmacokinetics and additional anti-ischaemic effectiveness of amlodipine, a once-daily calcium antagonist, during acute and long-term therapy of stable angina pectoris in patients pre-treated with a beta-blocker. | Q54041067 | ||
| Felodipine kinetics in healthy men. | Q54117719 | ||
| Effects of various doses of intracoronary diltiazem on coronary resistance vessels in humans. | Q54155646 | ||
| A comparison between the haemodynamic effects of oral nifedipine and intravenous dihydralazine in patients with severe pre-eclampsia | Q54169238 | ||
| Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group | Q54180877 | ||
| Long-term oral diazoxide therapy for pulmonary vascular obstructive disease associated with congenital heart defects. | Q54322476 | ||
| Nifedipine as an antihypertensive drug in patients with renal failure--pharmacokinetics and effects. | Q54324711 | ||
| Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension. | Q54374654 | ||
| Vascular selectivity of felodipine. | Q54457513 | ||
| Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol. | Q54457528 | ||
| Comparison of the acute hemodynamic effects of nifedipine with nitrendipine and a study of the electrophysiological effects of nitrendipine in man | Q54485933 | ||
| Minoxidil for severe hypertension after failure of other hypotensive drugs. | Q54594123 | ||
| The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: Comparison with patients with normal renal function | Q57986930 | ||
| The control of hypertension in patients undergoing regular maintenance hemodialysis | Q66844963 | ||
| Minoxidil Therapy in Refractory Hypertension Analysis of 155 Patients | Q66888516 | ||
| Pharmacokinetics of diltiazem in patients with liver cirrhosis | Q67241397 | ||
| Metabolism of diazoxide in man and experimental animals | Q67270308 | ||
| Renal Handling of Enalaprilat | Q67486041 | ||
| Increased pulmonary vascular resistance with systemic hypertension. Effect of minoxidil and other antihypertensive agents | Q67584182 | ||
| The Effect of Felodipine on the Sinus and Atrioventricular Nodes in Patients with Ischemic Heart Disease | Q67661225 | ||
| Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporin-treated renal transplant recipients | Q67848368 | ||
| Felodipine pharmacokinetics and plasma concentration vs effect relationships | Q67876762 | ||
| Palliative treatment of hyperinsulinism with cyproheptadine and diazoxide | Q67898394 | ||
| Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy | Q67915709 | ||
| The effect of three different oral doses of verapamil on the disposition of theophylline | Q68019070 | ||
| Intraindividual variability in nifedipine pharmacokinetics and effects in healthy subjects | Q68101285 | ||
| Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects | Q68111030 | ||
| Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist | Q68126850 | ||
| The combination of prazosin and verapamil in the treatment of essential hypertension | Q68136814 | ||
| Oral nifedipine pharmacokinetics in pregnancy-induced hypertension | Q68161837 | ||
| Interaction between cyclosporine and felodipine in renal transplant recipients | Q68174320 | ||
| The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide | Q68274283 | ||
| Verapamil pharmacokinetics and liver function in patients with cirrhosis | Q68392028 | ||
| Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis | Q68437542 | ||
| Minoxidil--an alternative to nephrectomy for refractory hypertension | Q68510756 | ||
| Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent | Q68560094 | ||
| Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function | Q68607461 | ||
| Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors | Q68642538 | ||
| Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis | Q68651393 | ||
| Pharmacokinetics of nifedipine after oral administration in chronic liver disease | Q68672884 | ||
| Dihydralazine hepatitis. Morphologic and clinical criteria for diagnosis | Q68756619 | ||
| The use of calcium antagonists in patients with renal failure | Q68783816 | ||
| P433 | issue | 6 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 457-482 | |
| P577 | publication date | 1998-06-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Clinical pharmacokinetics of vasodilators. Part I. | |
| P478 | volume | 34 |
| Q99581887 | A Case of Seronegative ANA Hydralazine-Induced Lupus Presenting With Pericardial Effusion and Pleural Effusion |
| Q43620208 | A validated method for the determination of verapamil and norverapamil in human plasma |
| Q39013181 | An angiotensin-converting enzyme (ACE) polymorphism may mitigate the effects of angiotensin-pathway medications on posttraumatic stress symptoms. |
| Q48793286 | Clinical pharmacokinetics of vasodilators. Part II. |
| Q47941602 | Drugs and Scaffold That Inhibit Cytochrome P450 27A1 In Vitro and In Vivo |
| Q37138222 | Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure |
| Q37679899 | Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers |
| Q34146073 | Metabolite parameters as an appropriate alternative approach for assessment of bioequivalence of two verapamil formulations |
| Q43983928 | Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation |
| Q43845769 | Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans |
| Q36237548 | Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension |
| Q37011696 | Selective opening of mitochondrial ATP-sensitive potassium channels during surgically induced myocardial ischemia decreases necrosis and apoptosis |
| Q37288580 | Severe hypertension in children and adolescents: pathophysiology and treatment |
| Q43856893 | Spectroscopic and HPLC studies of photodegradation of nilvadipine |
| Q46732265 | The association between nitroglycerin use and adverse outcomes in women undergoing cesarean delivery in the second stage of labor |
| Q34589838 | The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers |
| Q26849557 | Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics |
| Q38187598 | Therapy of acute hypertension in hospitalized children and adolescents |
| Q64924341 | [Which medications are safe while breastfeeding? : A synopsis for the anesthetist, obstetrician and pediatrician]. |
Search more.